Literature DB >> 1146441

[An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author's transl)].

V Hochstein-Mintzel, T Hänichen, H C Huber, H Stickl.   

Abstract

The attenuated MVA strain of vaccinia virus was previously shown to be innocuous and immunogenic at intracutaneous injection. It was therefore suggested for clinical trial. Preliminary results in human vaccinees are promising. The present experiments were initiated to study the intramuscular injection of the vaccine as a preferable route of administration. Histological examination was done in rabbits and monkeys. At the site of injection there were but minor inflammatory reactions considerably less pronounced than after the injection of commercial tetanus vaccine which was used for comparison. Intramuscular immunization with strain MVA repeated twice protected rabbits against an intravenous challenge with vaccinia strain Elstree; monkeys were protected against experimental smallpox. Intramuscular immunization with attenuated smallpox vaccine is suggested for clinical trial.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1146441

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Orig A        ISSN: 0300-9688


  15 in total

Review 1.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

2.  Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

Authors:  Gary Hermanson; Sookhee Chun; Jiin Felgner; Xiaolin Tan; Jozelyn Pablo; Rie Nakajima-Sasaki; Douglas M Molina; Philip L Felgner; Xiaowu Liang; D Huw Davies
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

3.  Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.

Authors:  Lewis H McCurdy; John A Rutigliano; Teresa R Johnson; Man Chen; Barney S Graham
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

4.  Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

Authors:  Zhiwei Chen; Linqi Zhang; Chuan Qin; Lei Ba; Christopher E Yi; Fengwen Zhang; Qiang Wei; Tian He; Wenjie Yu; Jian Yu; Hong Gao; Xinming Tu; Agegnehu Gettie; Michael Farzan; Kwok-Yung Yuen; David D Ho
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 5.  Replicating poxviruses for human cancer therapy.

Authors:  Manbok Kim
Journal:  J Microbiol       Date:  2015-04-08       Impact factor: 2.902

6.  Studies on poxvirus infections in irradiated animals.

Authors:  G T Werner; U Jentzsch; E Metzger; J Simon
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

7.  Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox.

Authors:  Peter B Jahrling; Lisa E Hensley; Mark J Martinez; James W Leduc; Kathleen H Rubins; David A Relman; John W Huggins
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

8.  Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.

Authors:  Sharon E Frey; Frances K Newman; Jeffrey S Kennedy; Vera Sobek; Francis A Ennis; Heather Hill; Lihan K Yan; Paul Chaplin; Jens Vollmar; Bernard R Chaitman; Robert B Belshe
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

9.  Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

Authors:  Sharon E Frey; Patricia L Winokur; Robert A Salata; Samer S El-Kamary; Christine B Turley; Emmanuel B Walter; Christine Mhorag Hay; Frances K Newman; Heather R Hill; Ying Zhang; Paul Chaplin; Magdalena Tary-Lehmann; Robert B Belshe
Journal:  Vaccine       Date:  2013-05-09       Impact factor: 3.641

Review 10.  A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication.

Authors:  Paulo H Verardi; Allison Titong; Caitlin J Hagen
Journal:  Hum Vaccin Immunother       Date:  2012-07-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.